alexa Biosimilar Globalization, A Silver Lining In Untested Waters! Biosimilars In China: Balance Of Risks And Opportunities
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th Asian Biologics and Biosimilars Congress
August 10-12, 2017 Beijing, China

Candida Fratazzi
Boston Biotech Clinical Research LLC, USA
Posters & Accepted Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-033
Abstract
Biotherapeutic products are the fastest growing medicines in the pharmaceutical market. Historically, 40% of China's $1.5 billion biologic product sales come from biosimilars, which have made approximately 25-30% of CAGR over the past decade. Today, the China biosimilar market is equivalent to ~20% of the global market. There are several factors driving the China biosimilar market: (1) Disease burden shifts from the infectious diseases to chronic diseases associated with diet and environmental changes, (2) Significant price discounts, around 60% compared to originator products, encourage reimbursements, (3) As the first wave of biologic originators hadn’t adequate protection on IPs in China, a number of Chinese players took advantage of this window of opportunity. Biosimilars represent a growing market that is still facing some major difficulties related to clinical trials and market penetration both in USA and EU. Twenty-four countries have already approved biosimilars. Nevertheless, biosimilars approval poses a number of substantial regulatory challenges for local regulatory authorities. Overall, the WHO perspective drives the similar biotherapeutic products globally. The WHO promotes a stepwise comparability exercise indicating that more work is done in pre-clinical comparability, less work is needed in clinical studies. The clinical requirements vary accordingly to existing knowledge of the reference product and the claimed therapeutic indications. Our presentation focuses on challenges that are common across the globe and impact cost and timelines in biosimilars’ development. Clinical studies are necessary to demonstrate comparative efficacy. In EU, UK and the Netherlands have invested resources for the validation of biosimilars in the marketplace by promoting clinical studies designed to answer physicians’ and patients’ uneasiness regarding biosimilars with immunogenicity being an element of uncertainty that can only be assessed in clinical trials. Extrapolation of safety and efficacy data can be justified from one indication to another with a comprehensive comparability program when the target receptor and the mechanism of action are identical. Specifically, the dialogue on extrapolation has elicited new interest as the FDA confronts core issues with special attention devoted to immunogenicity which must be always investigated with due consideration to risks in different indications. While most existing Chinese players follow a 'China for China' strategy, a few leading players with more advanced quality standards and manufacturing capabilities have set their sights on other less regulated emerging markets as well as developed markets. BBCR Consulting developed a framework based on evidence-based strategies and design-centered trials that identify the range of factors that affect the potential of cost saving in biosimilar development.
Biography

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version